Kivimäki Mika, Kuosma Eeva, Ferrie Jane E, Luukkonen Ritva, Nyberg Solja T, Alfredsson Lars, Batty G David, Brunner Eric J, Fransson Eleonor, Goldberg Marcel, Knutsson Anders, Koskenvuo Markku, Nordin Maria, Oksanen Tuula, Pentti Jaana, Rugulies Reiner, Shipley Martin J, Singh-Manoux Archana, Steptoe Andrew, Suominen Sakari B, Theorell Töres, Vahtera Jussi, Virtanen Marianna, Westerholm Peter, Westerlund Hugo, Zins Marie, Hamer Mark, Bell Joshua A, Tabak Adam G, Jokela Markus
Department of Epidemiology and Public Health, University College London, London, UK; Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Finnish Institute of Occupational Health, Helsinki, Finland.
Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Lancet Public Health. 2017 May 19;2(6):e277-e285. doi: 10.1016/S2468-2667(17)30074-9. eCollection 2017 Jun.
Although overweight and obesity have been studied in relation to individual cardiometabolic diseases, their association with risk of cardiometabolic multimorbidity is poorly understood. Here we aimed to establish the risk of incident cardiometabolic multimorbidity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in adults who are overweight and obese compared with those who are a healthy weight.
We pooled individual-participant data for BMI and incident cardiometabolic multimorbidity from 16 prospective cohort studies from the USA and Europe. Participants included in the analyses were 35 years or older and had data available for BMI at baseline and for type 2 diabetes, coronary heart disease, and stroke at baseline and follow-up. We excluded participants with a diagnosis of diabetes, coronary heart disease, or stroke at or before study baseline. According to WHO recommendations, we classified BMI into categories of healthy (20·0-24·9 kg/m), overweight (25·0-29·9 kg/m), class I (mild) obesity (30·0-34·9 kg/m), and class II and III (severe) obesity (≥35·0 kg/m). We used an inclusive definition of underweight (<20 kg/m) to achieve sufficient case numbers for analysis. The main outcome was cardiometabolic multimorbidity (ie, developing at least two from: type 2 diabetes, coronary heart disease, and stroke). Incident cardiometabolic multimorbidity was ascertained via resurvey or linkage to electronic medical records (including hospital admissions and death). We analysed data from each cohort separately using logistic regression and then pooled cohort-specific estimates using random-effects meta-analysis.
Participants were 120 813 adults (mean age 51·4 years, range 35-103; 71 445 women) who did not have diabetes, coronary heart disease, or stroke at study baseline (1973-2012). During a mean follow-up of 10·7 years (1995-2014), we identified 1627 cases of multimorbidity. After adjustment for sociodemographic and lifestyle factors, compared with individuals with a healthy weight, the risk of developing cardiometabolic multimorbidity in overweight individuals was twice as high (odds ratio [OR] 2·0, 95% CI 1·7-2·4; p<0·0001), almost five times higher for individuals with class I obesity (4·5, 3·5-5·8; p<0·0001), and almost 15 times higher for individuals with classes II and III obesity combined (14·5, 10·1-21·0; p<0·0001). This association was noted in men and women, young and old, and white and non-white participants, and was not dependent on the method of exposure assessment or outcome ascertainment. In analyses of different combinations of cardiometabolic conditions, odds ratios associated with classes II and III obesity were 2·2 (95% CI 1·9-2·6) for vascular disease only (coronary heart disease or stroke), 12·0 (8·1-17·9) for vascular disease followed by diabetes, 18·6 (16·6-20·9) for diabetes only, and 29·8 (21·7-40·8) for diabetes followed by vascular disease.
The risk of cardiometabolic multimorbidity increases as BMI increases; from double in overweight people to more than ten times in severely obese people compared with individuals with a healthy BMI. Our findings highlight the need for clinicians to actively screen for diabetes in overweight and obese patients with vascular disease, and pay increased attention to prevention of vascular disease in obese individuals with diabetes.
NordForsk, Medical Research Council, Cancer Research UK, Finnish Work Environment Fund, and Academy of Finland.
尽管超重和肥胖与个体的心血管代谢疾病之间的关系已得到研究,但其与心血管代谢疾病共病风险的关联却知之甚少。在此,我们旨在确定超重和肥胖成年人相较于体重正常者发生心血管代谢疾病共病(即2型糖尿病、冠心病和中风中至少两种疾病)的风险。
我们汇总了来自美国和欧洲16项前瞻性队列研究中关于体重指数(BMI)和心血管代谢疾病共病的个体参与者数据。纳入分析的参与者年龄在35岁及以上,且有基线BMI数据以及基线和随访时2型糖尿病、冠心病和中风的数据。我们排除了在研究基线时或之前被诊断为糖尿病、冠心病或中风的参与者。根据世界卫生组织的建议,我们将BMI分为健康(20.0 - 24.9kg/m²)、超重(25.0 - 29.9kg/m²)、I级(轻度)肥胖(30.0 - 34.9kg/m²)以及II级和III级(重度)肥胖(≥35.0kg/m²)几类。我们采用了一个包容性的体重过轻定义(<20kg/m²)以获得足够的病例数进行分析。主要结局是心血管代谢疾病共病(即发生2型糖尿病、冠心病和中风中至少两种疾病)。通过再次调查或与电子病历(包括住院和死亡记录)进行关联来确定心血管代谢疾病共病的发生情况。我们分别使用逻辑回归分析每个队列的数据,然后使用随机效应荟萃分析汇总特定队列的估计值。
参与者为120813名成年人(平均年龄51.4岁,范围35 - 103岁;71445名女性),他们在研究基线(1973 - 2012年)时没有糖尿病、冠心病或中风。在平均10.7年(1995 - 2014年)的随访期间,我们确定了1627例共病病例。在调整了社会人口学和生活方式因素后,与体重正常者相比,超重个体发生心血管代谢疾病共病的风险高出两倍(比值比[OR] 2.0,95%置信区间[CI] 1.7 - 2.4;p<0.0001),I级肥胖个体高出近五倍(4.5,3.5 - 5.8;p<0.0001),II级和III级肥胖个体合并高出近15倍(14.5,10.1 - 21.0;p<0.0001)。这种关联在男性和女性、年轻人和老年人、白人和非白人参与者中均有体现,并且不依赖于暴露评估或结局确定的方法。在对心血管代谢疾病不同组合的分析中,II级和III级肥胖与仅患血管疾病(冠心病或中风)的比值比为2.2(95% CI 1.9 - 2.6),患血管疾病后继发糖尿病的比值比为12.0(8.1 - 17.9),仅患糖尿病的比值比为18.6(16.6 - 20.9),患糖尿病后继发血管疾病的比值比为29.8(21.7 - 40.8)。
心血管代谢疾病共病的风险随着BMI的增加而增加;与BMI健康的个体相比,超重者的风险增加一倍,重度肥胖者的风险增加十多倍。我们的研究结果强调临床医生需要对患有血管疾病的超重和肥胖患者积极筛查糖尿病,并更加关注患有糖尿病的肥胖个体的血管疾病预防。
北欧研究理事会、医学研究理事会、英国癌症研究中心、芬兰工作环境基金和芬兰科学院。